Market Overview

UPDATE: Canaccord Genuity Raises PT to $56 on BioMarin Pharmaceutical on Value Inflection Outlook

Share:
Related BMRN
BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting
Benzinga's M&A Chatter for Monday August 24, 2015
Medivation Destined To Become Biotech Behemoth As Low Risk Pipeline Expands (Seeking Alpha)

Canaccord Genuity reiterated its Buy rating on BioMarin Pharmaceutical (NASDAQ: BMRN) and raised its price target from $52 to $56.

Canaccord Genuity noted, "We believe BMRN is at a key value inflection point as it enters 2013: a launch (GALNS), potential for three P3 programs (PEG-PAL in PKU, BMN-673 [PARP] in cancer and BMN-701 in Pompe) and clinical progress with two other drugs (BMN-190 in Batten disease [IND filing] and BMN-111 in achondroplasia enters P2), with details at the R&D day on Dec. 6 (highlighting ‘673 P1/2 data). While we are raising our price target to $56 (from $52), we note none of the pipeline ex-GALNS is included in our estimates – suggesting significant upside.

BioMarin Pharmaceutical closed at $37.41 on Friday.

Latest Ratings for BMRN

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Aug 2015Deutsche BankMaintainsBuy
Aug 2015Bank of AmericaMaintainsBuy

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!

Get Benzinga's Newsletters